Eli Lilly to acquire Kelonia for $7B

Kelonia's lead therapeutic candidate is designed to treat multiple myeloma in patients who have not responded to conventional treatments.

This strategic move positions Eli Lilly as a major player in the next generation of oncology therapies, moving beyond traditional cell manufacturing processes.

The deal includes significant milestone payments based on the success of clinical trials and regulatory approvals.

Investors are closely watching how this acquisition will integrate into Lilly's broader research and development pipeline.